Phase 2A Open-label Study to Evaluate Safety, Tolerability, and Antimicrobial Activity of Single, Daily Doses of SQ109 in Urea Breath Test Positive Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2015
At a glance
- Drugs SQ 109 (Primary)
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- Sponsors Sequella
- 16 Nov 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 14 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 14 May 2013 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.